VERICEL CORP ORD
NASDAQ: VCEL (Vericel Corporation)
Last update: 6 hours ago40.30
-0.32 (-0.79%)
| Previous Close | 40.62 |
| Open | 40.62 |
| Volume | 510,373 |
| Avg. Volume (3M) | 508,409 |
| Market Cap | 2,063,626,624 |
| Price / Earnings (TTM) | 85.74 |
| Price / Earnings (Forward) | 57.14 |
| Price / Sales | 6.65 |
| Price / Book | 5.37 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | 1.25% |
| Operating Margin (TTM) | -24.32% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 2.60% |
| Quarterly Earnings Growth (YOY) | 52.40% |
| Total Debt/Equity (MRQ) | 33.72% |
| Current Ratio (MRQ) | 5.01 |
| Operating Cash Flow (TTM) | 57.56 M |
| Levered Free Cash Flow (TTM) | -22.77 M |
| Return on Assets (TTM) | -0.45% |
| Return on Equity (TTM) | 1.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Vericel Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Relative Valuation | -5.0 |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | 0.86 |
Select this tab to load the latest available analysis.
|
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 107.99% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Congress Asset Management Co | 30 Sep 2026 | 2,552,066 |
| Conestoga Capital Advisors, Llc | 30 Jun 2026 | 2,083,832 |
| William Blair Investment Management, Llc | 30 Jun 2026 | 1,992,855 |
| Bnp Paribas Asset Management Holding S.A. | 30 Jun 2026 | 1,639,988 |
| Gw&K Investment Management, Llc | 30 Jun 2026 | 1,550,497 |
| Geneva Capital Management Llc | 30 Jun 2026 | 1,339,123 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |